Clinical Trial Update: A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 dose-ranging study evaluating the efficacy and safety of PF-06700841 in systemic lupus erythematosus and posted the results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• PF-06700841

Snippet

Sponsor: Pfizer | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2024-09-05